A 48-year-old man with chronic obstructive pulmonary disease (COPD) and hypertension is admitted with acute bronchospasm and wheezing. His current medications include atenolol 50 mg daily for blood pressure control. The emergency physician is considering bronchodilator therapy. Which of the following is the most appropriate immediate next step in management?

Explanation

## Clinical Context: Acute Bronchospasm in a COPD Patient on Atenolol This patient presents with acute bronchospasm while on atenolol (a β₁-selective blocker) for hypertension. The immediate priority is bronchodilation, and the long-term management of atenolol must be considered carefully. ## Immediate Management: Albuterol Nebulizer **Key Point:** Albuterol (salbutamol) is a **β₂-selective agonist** and is the **first-line agent** for acute bronchospasm in COPD. It should be administered immediately via nebulizer regardless of concurrent β-blocker use. - Onset: 5–15 minutes via nebulizer - Mechanism: Activates β₂-receptors on bronchial smooth muscle → bronchodilation - Even in the presence of a β₁-selective blocker, albuterol can overcome partial β₂-blockade and provide effective bronchodilation ## β₁-Selective Blockers in COPD: The Nuanced Reality **High-Yield:** Current evidence and major guidelines (GOLD, ESC/ERS) recognize that **β₁-selective blockers at low-to-moderate doses (e.g., atenolol 50 mg, metoprolol, bisoprolol) are NOT absolutely contraindicated in COPD** when there is a compelling cardiac indication (e.g., heart failure, post-MI, hypertension). This is a critical distinction from non-selective β-blockers. | β-Blocker Type | Bronchospasm Risk | Use in COPD | |---|---|---| | Non-selective (propranolol) | Very high | Contraindicated | | β₁-selective (atenolol 50 mg, metoprolol, bisoprolol) | Low–moderate | **Relative contraindication; may be continued with monitoring** | At standard doses (atenolol 50 mg), the β₁:β₂ selectivity ratio (~10:1) means that β₂-mediated bronchodilation is largely preserved. Abruptly discontinuing atenolol in a hypertensive patient without a clear plan is not the immediate priority during an acute bronchospasm episode. ## Why Option C Is Incorrect Option C recommends **discontinuing atenolol and switching to a calcium channel blocker** as part of the immediate next step. While long-term reassessment of atenolol is reasonable, **abrupt discontinuation of a β-blocker** carries risks (rebound hypertension, tachycardia) and is NOT the immediate priority in acute bronchospasm management. The acute step is bronchodilation; medication reconciliation follows stabilization. ## Why Option D Is Correct **Clinical Pearl:** Administering albuterol via nebulizer addresses the acute bronchospasm immediately. Continuing atenolol at this dose (50 mg) is defensible because: 1. β₁-selectivity at this dose minimizes β₂-blockade 2. Abrupt discontinuation is not indicated emergently 3. The cardiac benefit (blood pressure control) is maintained 4. Albuterol effectively counteracts any residual β₂-blockade This reflects the **best next step** in the acute setting — treat the bronchospasm first, then reassess antihypertensive therapy electively. ## Why Other Options Are Incorrect - **Option A:** Ipratropium alone is insufficient for acute bronchospasm; albuterol is the primary agent - **Option B:** Theophylline IV is not first-line; abrupt atenolol cessation is not indicated emergently **Mnemonic:** In acute bronchospasm — **"Treat the airway first, then reassess the heart meds."** [cite: GOLD Guidelines 2023; Harrison's Principles of Internal Medicine 21e Ch 256; KD Tripathi Essentials of Medical Pharmacology 8e Ch 10; Salpeter SR et al., Ann Intern Med 2002 — cardioselective β-blockers in COPD]